Correvio Pharma Corp (NASDAQ: CORV)( TSX: CORV), a specialty pharmaceutical company focused on commercialising hospital drugs, announced yesterday its financial results for its first quarter ended 31 March 2019.

The company reported a net loss of USD9m for the three months ended 31March 2019, compared to a net loss of USD8.5m in the year-ago period.

The firm posted revenue for the three months ended 31 March 2019 at USD7.3m compared to revenue of USD6.5m in the year-ago period.

Mark HN Corrigan, MD, CEO of Correvio, said, 2019 is off to a strong start with first quarter revenues up 16% year-over-year in local currencies. Our first quarter revenues from Xydalba and Zevtera doubled year-over-year. Looking ahead, we remain on track to resubmit the New Drug Application seeking approval in the US for BrinavessTM as a new treatment for adult patients with recent onset atrial fibrillation during the second quarter of 2019.'